Contribution of congenital cytomegalovirus (cCMV) to permanent hearing loss in a highly seropositive population: "The BraCHS study".
The exact contribution of congenital CMV infection (cCMV) to congenital and early-onset permanent hearing loss in highly seropositive populations is unknown. To determine the contribution of the cCMV to hearing impairment and to estimate the effectiveness of newborn hearing screening (HS) in identifying infants with CMV-related hearing loss. A total of 11,900 infants born from a population with ≥97% maternal seroprevalence were screened for cCMV and hearing loss. cCMV was confirmed by detection of CMV-DNA in saliva and urine <3 weeks of age. Overall, 68 (0.6%; CI95%:0.4-0.7) neonates were identified with cCMV. Of the 91 (0.8%) infants who failed HS, 24 (26.4%) were confirmed with hearing loss (HL) including 7 (29.2%; CI95%:17.2-59.3) with cCMV. Another infant with cCMV passed HS but was confirmed with HL at 21 days of age. Of the 62 infants with cCMV who underwent complete hearing evaluation, 8 (12.9%; CI95%: 6.7-23.4) had HL and most (7/8; 87.5%; CI95%:46.6-99.7) were identified by HS. The rate of permanent HL resulting from cCMV was 8 per 11,887 infants (0.7 per 1000 live births). The prevalence ratio of hearing loss among infants with cCMV compared to CMV-uninfected infants was 89.5 (CI95%:39.7-202.0). No late onset of CMV-related HL was detected during a median follow-up of 36 months. cCMV is an important cause of permanent hearing impairment in childhood in all settings. Integrating targeted cCMV screening among infants who fail HS could be a reasonable cost-effective strategy to identify infants with early onset of cCMV-related HL.